Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?
Key takeaways
- Amtagvi Approval Boosted Iovance Biotherapeutics, Inc.
- On June 4, The Fly reported that Iovance Biotherapeutics, Inc.
- Overall, 80% of the analysts are bullish on Iovance Biotherapeutics, Inc.
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last? Rameen Kasana Sat, June 13, 2026 at 10:30 PM GMT+7 2 min read IOVA Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated following the Australian approval of Amtagvi. The stock has returned to its pre-approval levels.
On June 4, The Fly reported that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has received conditional approval of Amtagvi from the Therapeutic Goods Administration of Australia. This marks the third marketing authorization for Amtagvi, underscoring a huge step forward in a market with the highest rate of melanoma globally.
Overall, 80% of the analysts are bullish on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), with the remaining 20% neutral. On May 8, Chardan trimmed the price target on the company from $16 to $14 and reiterated a Buy rating. In a research note, the analyst attributed this model readjustment to the revised Amtagvi launch guidance. Management now forecasts Q2 Amtagvi revenue to be between $79 million and $81 million. With this potential, the company has secured a spot among the hidden penny stocks to invest in.